Insight Molecular Diagnostics Inc. (IMDX) stock
IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$1.78−0.08 (-4.30%)
Close on Nov 17, 2026Market cap $58.25MP/E –Yield –
Insight Molecular Diagnostics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Insight Molecular Diagnostics's operating cash flow for the twelve months ending Jun 30, 2026 was -$27.08M. For fiscal 2025 it was -$22.18M. The highest annual figure on record is -$1.16M in fiscal 2014.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.18M | – |
| FY2024 | Dec 31, 2024 | -$20.69M | – |
| FY2023 | Dec 31, 2023 | -$23.33M | – |
| FY2022 | Dec 31, 2022 | -$45.57M | – |
| FY2021 | Dec 31, 2021 | -$35.94M | – |
| FY2020 | Dec 31, 2020 | -$25.98M | – |
| FY2019 | Dec 31, 2019 | -$19.72M | – |
| FY2018 | Dec 31, 2018 | -$11.65M | – |
| FY2017 | Dec 31, 2017 | -$13.39M | – |
| FY2016 | Dec 31, 2016 | -$7.52M | – |
| FY2015 | Dec 31, 2015 | -$4.23M | – |
| FY2014 | Dec 31, 2014 | -$1.16M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.27M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.64M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.84M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.53M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.98M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.42M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.65M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.40M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.25M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.28M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.98M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.06M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.84M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.14M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.96M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.87M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.31M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.85M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.72M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.46M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.48M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.96M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.75M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.34M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.47M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.28M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.29M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.51M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.03M | – |
See a number that looks wrong?